LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Alvotech SA

Geschlossen

BrancheGesundheitswesen

10.65 1.72

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

10.38

Max

10.76

Schlüsselkennzahlen

By Trading Economics

Einkommen

177M

110M

Verkäufe

-18M

133M

KGV

Branchendurchschnitt

30.311

51.198

EPS

0.363

Gewinnspanne

82.612

Angestellte

1,012

EBITDA

257M

137M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+166.67% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

13. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

291M

3.4B

Vorheriger Eröffnungskurs

8.93

Vorheriger Schlusskurs

10.65

Nachrichtenstimmung

By Acuity

9%

91%

8 / 380 Ranking in Healthcare

Alvotech SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Apr. 2025, 14:54 UTC

Ergebnisse

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

Peer-Vergleich

Kursveränderung

Alvotech SA Prognose

Kursziel

By TipRanks

166.67% Vorteil

12-Monats-Prognose

Durchschnitt 28 USD  166.67%

Hoch 28 USD

Tief 28 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Alvotech SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

1 ratings

1

Buy

0

Halten

0

Sell

Stimmung

By Acuity

8 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Alvotech SA

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.